Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Pentaborate Pentahydrate in Alzheimer's Disease
NCT06840054Phase 2Not yet recruiting
- Sponsor
- Tabriz University of Medical Sciences
- Start
- May 2025
- Primary completion
- Jan 2026
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 2, randomised, double-blind trial of sodium pentaborate pentahydrate in Alzheimer's disease (AD) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoint: Alzheimer's Disease Assessment Scale - Cognitive Subscale at 6 months. Planned start May 2025; status: not yet recruiting.
02
Drugs
sodium pentaborate pentahydrate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06840054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06840054.